Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Med Genet. Oct 2003; 40(10): 721–728.
PMCID: PMC1735296

In vivo reversion to normal of inherited mutations in humans

Full Text

The Full Text of this article is available as a PDF (225K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hall JG. Review and hypotheses: somatic mosaicism: observations related to clinical genetics. Am J Hum Genet. 1988 Oct;43(4):355–363. [PMC free article] [PubMed]
  • Zlotogora J. Germ line mosaicism. Hum Genet. 1998 Apr;102(4):381–386. [PubMed]
  • Wahn V, Stephan V, Hirschhorn R. Reverse mutations--spontaneous amelioration or cure of inherited disorders? Eur J Pediatr. 1998 Aug;157(8):613–617. [PubMed]
  • Jonkman MF. Revertant mosaicism in human genetic disorders. Am J Med Genet. 1999 Aug 6;85(4):361–364. [PubMed]
  • Youssoufian Hagop, Pyeritz Reed E. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002 Oct;3(10):748–758. [PubMed]
  • HIRSCHHORN K, DECKER WH, COOPER HL. Human intersex with chromosome mosaicism of type XY/XO. Report of a case. N Engl J Med. 1960 Nov 24;263:1044–1048. [PubMed]
  • Robinson WP, Binkert F, Bernasconi F, Lorda-Sanchez I, Werder EA, Schinzel AA. Molecular studies of chromosomal mosaicism: relative frequency of chromosome gain or loss and possible role of cell selection. Am J Hum Genet. 1995 Feb;56(2):444–451. [PMC free article] [PubMed]
  • Sippel KC, Fraioli RE, Smith GD, Schalkoff ME, Sutherland J, Gallie BL, Dryja TP. Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am J Hum Genet. 1998 Mar;62(3):610–619. [PMC free article] [PubMed]
  • Hamm H. Cutaneous mosaicism of lethal mutations. Am J Med Genet. 1999 Aug 6;85(4):342–345. [PubMed]
  • Van den Veyver IB. Skewed X inactivation in X-linked disorders. Semin Reprod Med. 2001 Jun;19(2):183–191. [PubMed]
  • Liehr T, Rautenstrauss B, Grehl H, Bathke KD, Ekici A, Rauch A, Rott HD. Mosaicism for the Charcot-Marie-Tooth disease type 1A duplication suggests somatic reversion. Hum Genet. 1996 Jul;98(1):22–28. [PubMed]
  • Fanin M, Danieli GA, Vitiello L, Senter L, Angelini C. Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients. Neuromuscul Disord. 1992;2(1):41–45. [PubMed]
  • Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol. 2001 May-Jun;4(3):212–221. [PubMed]
  • Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest. 1993 Apr;91(4):1816–1821. [PMC free article] [PubMed]
  • Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P. Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest. 1994 Oct;94(4):1657–1661. [PMC free article] [PubMed]
  • Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab. 1998 Jun;64(2):119–125. [PubMed]
  • Dreumont N, Poudrier JA, Bergeron A, Levy HL, Baklouti F, Tanguay RM. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation. BMC Genet. 2001;2:9–9. [PMC free article] [PubMed]
  • Overturf K, Al-Dhalimy M, Tanguay R, Brantly M, Ou CN, Finegold M, Grompe M. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet. 1996 Mar;12(3):266–273. [PubMed]
  • Hirschhorn R, Yang DR, Israni A, Huie ML, Ownby DR. Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery. Am J Hum Genet. 1994 Jul;55(1):59–68. [PMC free article] [PubMed]
  • Hirschhorn R, Yang DR, Puck JM, Huie ML, Jiang CK, Kurlandsky LE. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet. 1996 Jul;13(3):290–295. [PubMed]
  • Ariga T, Oda N, Yamaguchi K, Kawamura N, Kikuta H, Taniuchi S, Kobayashi Y, Terada K, Ikeda H, Hershfield MS, et al. T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood. 2001 May 1;97(9):2896–2899. [PubMed]
  • Arredondo-Vega Francisco X, Santisteban Ines, Richard Eva, Bali Pawan, Koleilat Majed, Loubser Michael, Al-Ghonaium Abdulaziz, Al-Helali Mariam, Hershfield Michael S. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood. 2002 Feb 1;99(3):1005–1013. [PubMed]
  • De Berardinis P, Ombra MN, Buono C, Toraldo R, Vetrano F, Guardiola J. Long-term culture and T cell receptor analysis of T cell clones isolated from a patient with adenosine deaminase deficiency and type I diabetes. Clin Immunol Immunopathol. 1994 Dec;73(3):362–366. [PubMed]
  • Misaki Y, Ezaki I, Ariga T, Kawamura N, Sakiyama Y, Yamamoto K. Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy. Mol Ther. 2001 Jan;3(1):24–27. [PubMed]
  • Aiuti Alessandro, Slavin Shimon, Aker Memet, Ficara Francesca, Deola Sara, Mortellaro Alessandra, Morecki Shoshana, Andolfi Grazia, Tabucchi Antonella, Carlucci Filippo, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002 Jun 28;296(5577):2410–2413. [PubMed]
  • Aiuti Alessandro, Vai Sergio, Mortellaro Alessandra, Casorati Giulia, Ficara Francesca, Andolfi Grazia, Ferrari Giuliana, Tabucchi Antonella, Carlucci Filippo, Ochs Hans D, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002 May;8(5):423–425. [PubMed]
  • Press NA, Yasui Y, Reynolds S, Durfy SJ, Burke W. Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. Am J Med Genet. 2001 Mar 1;99(2):99–110. [PubMed]
  • Stephan V, Wahn V, Le Deist F, Dirksen U, Broker B, Müller-Fleckenstein I, Horneff G, Schroten H, Fischer A, de Saint Basile G. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 1996 Nov 21;335(21):1563–1567. [PubMed]
  • Bousso P, Wahn V, Douagi I, Horneff G, Pannetier C, Le Deist F, Zepp F, Niehues T, Kourilsky P, Fischer A, et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):274–278. [PMC free article] [PubMed]
  • Kume A, Koremoto M, Mizukami H, Okada T, Hanazono Y, Sugamura K, Ozawa K. Selective growth advantage of wild-type lymphocytes in X-linked SCID recipients. Bone Marrow Transplant. 2002 Jul;30(2):113–118. [PubMed]
  • Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000 Apr 28;288(5466):669–672. [PubMed]
  • Hacein-Bey-Abina Salima, Le Deist Françoise, Carlier Frédérique, Bouneaud Cécile, Hue Christophe, De Villartay Jean-Pierre, Thrasher Adrian J, Wulffraat Nicolas, Sorensen Ricardo, Dupuis-Girod Sophie, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002 Apr 18;346(16):1185–1193. [PubMed]
  • Fischer Alain, Hacein-Bey Salima, Cavazzana-Calvo Marina. Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol. 2002 Aug;2(8):615–621. [PubMed]
  • Hacein-Bey-Abina Salima, von Kalle Christof, Schmidt Manfred, Le Deist Françoise, Wulffraat Nicolas, McIntyre Elisabeth, Radford Isabelle, Villeval Jean-Luc, Fraser Christopher C, Cavazzana-Calvo Marina, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003 Jan 16;348(3):255–256. [PubMed]
  • Ariga T, Kondoh T, Yamaguchi K, Yamada M, Sasaki S, Nelson DL, Ikeda H, Kobayashi K, Moriuchi H, Sakiyama Y. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J Immunol. 2001 Apr 15;166(8):5245–5249. [PubMed]
  • Wada T, Schurman SH, Otsu M, Garabedian EK, Ochs HD, Nelson DL, Candotti F. Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8697–8702. [PMC free article] [PubMed]
  • Ariga T, Yamada M, Sakiyama Y, Tatsuzawa O. A case of Wiskott-Aldrich syndrome with dual mutations in exon 10 of the WASP gene: an additional de novo one-base insertion, which restores frame shift due to an inherent one-base deletion, detected in the major population of the patient's peripheral blood lymphocytes. Blood. 1998 Jul 15;92(2):699–701. [PubMed]
  • Ellis NA, Ciocci S, German J. Back mutation can produce phenotype reversion in Bloom syndrome somatic cells. Hum Genet. 2001 Feb;108(2):167–173. [PubMed]
  • Jonkman MF, Scheffer H, Stulp R, Pas HH, Nijenhuis M, Heeres K, Owaribe K, Pulkkinen L, Uitto J. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell. 1997 Feb 21;88(4):543–551. [PubMed]
  • Darling TN, Yee C, Bauer JW, Hintner H, Yancey KB. Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation. J Clin Invest. 1999 May 15;103(10):1371–1377. [PMC free article] [PubMed]
  • Schuilenga-Hut Petra H L, Scheffer Hans, Pas Hendri H, Nijenhuis Miranda, Buys Charles H C M, Jonkman Marcel F. Partial revertant mosaicism of keratin 14 in a patient with recessive epidermolysis bullosa simplex. J Invest Dermatol. 2002 Apr;118(4):626–630. [PubMed]
  • Tischkowitz MD, Hodgson SV. Fanconi anaemia. J Med Genet. 2003 Jan;40(1):1–10. [PMC free article] [PubMed]
  • Meetei Amom Ruhikanta, Sechi Salvatore, Wallisch Michael, Yang Dafeng, Young Mary K, Joenje Hans, Hoatlin Maureen E, Wang Weidong. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol. 2003 May;23(10):3417–3426. [PMC free article] [PubMed]
  • Waisfisz Q, Morgan NV, Savino M, de Winter JP, van Berkel CG, Hoatlin ME, Ianzano L, Gibson RA, Arwert F, Savoia A, et al. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet. 1999 Aug;22(4):379–383. [PubMed]
  • Lo Ten Foe JR, Kwee ML, Rooimans MA, Oostra AB, Veerman AJ, van Weel M, Pauli RM, Shahidi NT, Dokal I, Roberts I, et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet. 1997 May-Jun;5(3):137–148. [PubMed]
  • Gross M, Hanenberg H, Lobitz S, Friedl R, Herterich S, Dietrich R, Gruhn B, Schindler D, Hoehn H. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res. 2002;98(2-3):126–135. [PubMed]
  • Gregory JJ, Jr, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR, Steffenhagen A, Hirsch B, Auerbach AD. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2532–2537. [PMC free article] [PubMed]
  • Gush KA, Fu KL, Grompe M, Walsh CE. Phenotypic correction of Fanconi anemia group C knockout mice. Blood. 2000 Jan 15;95(2):700–704. [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...